Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

D J Storey; M Sakala; C M McLean; H A Phillips; L K Dawson; L R Wall; M T Fallon; S Clive

doi:10.1093/annonc/mdp594

Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

D J Storey, M Sakala, C M McLean, H A Phillips, L K Dawson, L R Wall, M T Fallon, S Clive

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx.

Original language	English
Pages (from-to)	1657-1661
Number of pages	5
Journal	Annals of Oncology
Volume	21
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdp594
Publication status	Published - 2010

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine
Fluorouracil
Humans
Incidence
Middle Aged
Organoplatinum Compounds
Peripheral Nervous System Diseases
Retrospective Studies
Scotland

Access to Document

10.1093/annonc/mdp594

Cite this

@article{5372dca8403b4f16b063ca2cb6b42cd7,

title = "Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?",

abstract = "There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Fluorouracil, Humans, Incidence, Middle Aged, Organoplatinum Compounds, Peripheral Nervous System Diseases, Retrospective Studies, Scotland",

author = "Storey, {D J} and M Sakala and McLean, {C M} and Phillips, {H A} and Dawson, {L K} and Wall, {L R} and Fallon, {M T} and S Clive",

year = "2010",

doi = "10.1093/annonc/mdp594",

language = "English",

volume = "21",

pages = "1657--1661",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Capecitabine combined with oxaliplatin (CapOx) in clinical practice

T2 - how significant is peripheral neuropathy?

AU - Storey, D J

AU - Sakala, M

AU - McLean, C M

AU - Phillips, H A

AU - Dawson, L K

AU - Wall, L R

AU - Fallon, M T

AU - Clive, S

PY - 2010

Y1 - 2010

N2 - There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx.

AB - There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Deoxycytidine

KW - Fluorouracil

KW - Humans

KW - Incidence

KW - Middle Aged

KW - Organoplatinum Compounds

KW - Peripheral Nervous System Diseases

KW - Retrospective Studies

KW - Scotland

UR - http://www.scopus.com/inward/record.url?scp=77955257293&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp594

DO - 10.1093/annonc/mdp594

M3 - Article

C2 - 20089559

SN - 0923-7534

VL - 21

SP - 1657

EP - 1661

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Other files and links

Fingerprint

Cite this